http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103160588-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_653c418e41edbb4e1ce8bc5e53e70cec |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2013-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4832f6ec634650b5f090c39316ad9641 |
| publicationDate | 2014-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103160588-B |
| titleOfInvention | Atherosclerosis-related serum miRNA (microribonucleic acid) marker group, and specific primers and application thereof |
| abstract | The invention relates to an atherosclerosis-related serum miRNA (microribonucleic acid) marker group, and specific primers and application thereof. The marker group comprises a miR-135b marker of which the nucleotide sequence is shown as SEQ ID NO.1 and a miR-499a-3p marker of which the nucleotide sequence is shown as SEQ ID NO.2. The invention also relates to specific primers and application of the miRNA marker group. The two markers screened out from the serum miRNA marker group provided by the invention have high complementarity, thereby ensuring that the detection is quantitatively precise and greatly improving the sensitivity and specificity of disease diagnosis. |
| priorityDate | 2013-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 89.